$6.00
0.33% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US88032L2097
Symbol
TENX

Tenax Therapeutics, Inc. Stock price

$6.00
+0.86 16.73% 1M
+1.23 25.78% 6M
-0.19 3.07% YTD
+2.23 59.15% 1Y
-1,011.60 99.41% 3Y
-1,978.00 99.70% 5Y
-111,034.00 99.99% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.02 0.33%
ISIN
US88032L2097
Symbol
TENX
Sector

Key metrics

Market capitalization $24.89m
Enterprise Value $-86.56m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 5.21
P/B ratio (TTM) P/B ratio 0.22
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-26.92m
Free Cash Flow (TTM) Free Cash Flow $-16.61m
Cash position $111.45m
EPS (TTM) EPS $-2.48
Short interest 7.68%
Show more

Is Tenax Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Tenax Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Tenax Therapeutics, Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Tenax Therapeutics, Inc. forecast:

Buy
100%

Financial data from Tenax Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
126% 126%
-
- Research and Development Expense 16 16
179% 179%
-
-27 -27
154% 154%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -27 -27
154% 154%
-
Net Profit -24 -24
140% 140%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tenax Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tenax Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
6 days ago
Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026
Positive
Seeking Alpha
about one month ago
Tenax Therapeutics is advancing levosimendan in two phase 3 studies for PH-HFpEF, with LEVEL-2 starting in 2025 and topline data from LEVEL expected mid-2026. Levosimendan could be the first disease-modifying therapy for PH-HFpEF, with prior phase 2 success in improving exercise capacity. The company raised $25 million in March 2025, ensuring sufficient funding through 2027 to meet clinical mil...
Neutral
GlobeNewsWire
about 2 months ago
CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place virtually from A...
More Tenax Therapeutics, Inc. News

Company Profile

Tenax Therapeutics, Inc. engages in the identification, development, and commercialization of novel therapeutic products for the critical care market. Its lead product candidate is Levosimendan, a calcium sensitizer activator for intravenous use in hospitalized patients with acutely decompensated heart failure. The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.

Head office United States
CEO Christopher Giordano
Employees 6
Founded 1967
Website www.tenaxthera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today